Ablynx beats GSK's Domantis in patent appeal
This article was originally published in Scrip
Executive Summary
Ablynx has scored a small victory against GlaxoSmithKline subsidiary Domantis, successfully opposing Domantis's appeal to have one of its patents reinstated.